Gabapentin Dosing in Elderly Patients
Start gabapentin at 100-200 mg once daily in elderly patients, with dose escalation every 3-7 days based on tolerability, and always adjust dosing based on creatinine clearance using the Cockcroft-Gault equation. 1
Initial Dosing Strategy
In elderly patients, the standard adult starting dose must be reduced due to age-related decline in renal function. The FDA label explicitly recommends dose adjustment in elderly patients because they are more likely to have decreased renal function 1. Begin with:
- 100-200 mg once daily (not the standard 300 mg three times daily used in younger adults)
- For patients with moderate or greater renal impairment, use the lowest starting dose (100 mg daily) 2
- Increase incrementally at intervals long enough to monitor for adverse effects—typically every 3-7 days 2
Renal Function-Based Dosing
Critical: Calculate creatinine clearance using the Cockcroft-Gault equation 3. This is the method used in clinical trials and FDA approval, not eGFR/MDRD4. Using MDRD4 would result in 37% higher gabapentin doses and significantly increase toxicity risk, particularly in elderly women 4.
Specific Dose Adjustments by Creatinine Clearance 1:
CrCl ≥60 mL/min:
- Total daily dose: 900-3600 mg/day
- Regimen: 300-1200 mg three times daily
CrCl 30-59 mL/min:
- Total daily dose: 400-1400 mg/day
- Regimen: 200-700 mg twice daily
CrCl 15-29 mL/min:
- Total daily dose: 200-700 mg/day
- Regimen: 200-700 mg once daily
CrCl <15 mL/min:
- Total daily dose: 100-300 mg/day
- Regimen: 100-300 mg once daily
- For CrCl <15 mL/min, reduce daily dose proportionally (e.g., CrCl of 7.5 mL/min receives half the dose for CrCl 15 mL/min)
Hemodialysis patients:
- Maintenance dose based on CrCl as above
- Plus supplemental post-dialysis dose of 125-350 mg after each 4-hour dialysis session 1
Pharmacokinetic Rationale
Gabapentin clearance declines significantly with age, dropping from ~225 mL/min in patients under 30 to ~125 mL/min in those over 70 1. This decline is entirely explained by reduced renal function 5. The elimination half-life increases from 6.5 hours in patients with normal renal function to 52 hours in those with CrCl <30 mL/min 1. In anuric patients, the half-life extends to 132 hours 1.
Titration and Maintenance
The effective dose in elderly patients is typically lower than the standard adult range of 1800-3600 mg/day 2. For neuropathic pain:
- Effective pregabalin doses: 150-600 mg/day (divided twice daily)
- Effective gabapentin doses: 900-3600 mg/day (divided 2-3 times daily)
- Elderly patients often respond to the lower end of these ranges 2
Maximum time between doses should not exceed 12 hours 1.
Critical Safety Considerations
Adverse effects are particularly problematic in elderly patients 2:
- Somnolence, dizziness, and mental clouding are common
- Recent data shows gabapentin prescription is associated with increased dementia risk (RR 1.29) and mild cognitive impairment (RR 1.85), with risk increasing with prescription frequency 6
- Risk is particularly elevated in non-elderly adults (18-64), suggesting vigilance is needed across all age groups
When discontinuing or reducing gabapentin, taper gradually over minimum 1 week (longer periods may be needed) 1.
Common Pitfalls to Avoid
- Do not use eGFR/MDRD4 for dose calculation—this will result in overdosing, especially in elderly women 4
- Do not start at standard adult doses—elderly patients require lower starting doses even with normal calculated CrCl due to age-related pharmacokinetic changes 5
- Do not ignore cognitive monitoring—given emerging dementia risk data, monitor cognitive function during chronic therapy 6
- Do not assume linear dose-response—gabapentin has saturable absorption, and doses above 1800 mg/day may not provide additional benefit 1, 7